Prediction of drug metabolism: The case of cytochrome P450 2D6

被引:55
作者
Vermeulen, NPE [1 ]
机构
[1] Vrije Univ Amsterdam, Sect Mol Toxicol, Dept Pharmacochem, LACDR, NL-1081 HV Amsterdam, Netherlands
关键词
cytochrome P450 2D6; drug metabolism; drug discovery and development; in silico prediction; high-throughput screening;
D O I
10.2174/1568026033451998
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cytochromes P450 (Cyt P450s) constitute the most important biotransformation enzymes involved in the biotransformation of drugs and other xenobiotics. Because drug metabolism by Cyt P450s plays such an important role in the disposition and in the pharmacological and toxicological effects of drugs, early consideration of ADME-properties is increasingly seen as essential for the discovery and the development of new drugs and drug candidates. the primary aim of this paper is to present various Computational approaches used to rationalize and predict the activity and substrate selectivity of Cyt P450s, as well as the possibilities and limitations of these approaches, now and in the future. Attention is also paid to the experimental validation of these approaches by using high-throughput screening (HTS) of affinities to drug-drug interactions at the level of Cyt P450-isoenzymes. Since human Cyt P450 2D6 is one of the most important drug metabolizing enzymes and since in this regard much pioneering work has been done with this Cyt P450, Cyt P450 2D6 is chosen as a model for this discussion. Apart from early rnechanism-based ab initio calculations on substrates of Cyt P450 2D6, pharmacophore modeling of ligands (i.e. both substrates and inhibitors) of Cyt P450 2D6 and protein homology modeling have been used succesfully for the rationalisation and prediction of metabolite formation by this Cyt P450 isoenzyme. Significant protein structure-related species differences have been reported recently. It is concluded that not one computational approach is capable of rationalizing and reliably predicting metabolite formation by Cyt P450 2D6, but that it is rather the combination of the various complimentary approaches. It is moreover concluded, that experimental validation of the computational models and predictions is often still lacking. With the advent of novel, easily and well applicable in vitro based high throughput assays for ligand binding and turnover this limitation could be overcome soon, however. When effective links with other new and recent developments, such as bioinformatics, neural network computing, genomics and proteomics can be created, in silico rationalisation and prediction of drug metabolism by Cyt P450s is likely to become one of the key technologies in early drug discovery and development processes.
引用
收藏
页码:1227 / 1239
页数:13
相关论文
共 70 条
[21]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491
[22]   OXYGEN AND XENOBIOTIC REDUCTASE ACTIVITIES OF CYTOCHROME-P450 [J].
GOEPTAR, AR ;
SCHEERENS, H ;
VERMEULEN, NPE .
CRITICAL REVIEWS IN TOXICOLOGY, 1995, 25 (01) :25-65
[23]   P450s: Structural similarities and functional differences [J].
GrahamLorence, S ;
Peterson, JA .
FASEB JOURNAL, 1996, 10 (02) :206-214
[24]   A 3-DIMENSIONAL MODEL OF AROMATASE CYTOCHROME-P450 [J].
GRAHAMLORENCE, S ;
AMARNEH, B ;
WHITE, RE ;
PETERSON, JA ;
SIMPSON, ER .
PROTEIN SCIENCE, 1995, 4 (06) :1065-1080
[25]   STRUCTURE AND FUNCTION OF CYTOCHROMES-P450 - A COMPARATIVE-ANALYSIS OF 3 CRYSTAL-STRUCTURES [J].
HASEMANN, CA ;
KURUMBAIL, RG ;
BODDUPALLI, SS ;
PETERSON, JA ;
DEISENHOFER, J .
STRUCTURE, 1995, 3 (01) :41-62
[26]   CRYSTAL-STRUCTURE AND REFINEMENT OF CYTOCHROME P450(TERP) AT 2-CENTER-DOT-3 ANGSTROM RESOLUTION [J].
HASEMANN, CA ;
RAVICHANDRAN, KG ;
PETERSON, JA ;
DEISENHOFER, J .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 236 (04) :1169-1185
[27]   A NEW METHOD FOR BUILDING PROTEIN CONFORMATIONS FROM SEQUENCE ALIGNMENTS WITH HOMOLOGS OF KNOWN STRUCTURE [J].
HAVEL, TF ;
SNOW, ME .
JOURNAL OF MOLECULAR BIOLOGY, 1991, 217 (01) :1-7
[28]   ADMET - turning chemicals into drugs [J].
Hodgson, J .
NATURE BIOTECHNOLOGY, 2001, 19 (08) :722-726
[29]   Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment [J].
Ingelman-Sundberg, M ;
Oscarson, M ;
McLellan, RA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (08) :342-349
[30]   A SINGLE AMINO-ACID SUBSTITUTION CONVERTS CYTOCHROME-P450(14DM) TO AN INACTIVE FORM, CYTOCHROME-P450(SG1) - COMPLETE PRIMARY STRUCTURES DEDUCED FROM CLONED DNAS [J].
ISHIDA, N ;
AOYAMA, Y ;
HATANAKA, R ;
OYAMA, Y ;
IMAJO, S ;
ISHIGURO, M ;
OSHIMA, T ;
NAKAZATO, H ;
NOGUCHI, T ;
MAITRA, US ;
MOHAN, VP ;
SPRINSON, DB ;
YOSHIDA, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 155 (01) :317-323